Organon & Co. (NYSE:OGN) Hits New 12-Month High – What’s Next?

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $13.88 and last traded at $13.8550, with a volume of 151,651 shares traded. The stock had previously closed at $13.85.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Price Performance

The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 1.27 and a beta of 1.53. The company has a current ratio of 2.02, a quick ratio of 1.44 and a debt-to-equity ratio of 7.11. The company’s 50 day simple moving average is $13.75 and its 200-day simple moving average is $11.53.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Friday, October 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.58 billion. Organon & Co. had a net margin of 3.49% and a return on equity of 82.06%. On average, equities research analysts predict that Organon & Co. will post 3.24 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Monday, November 9th will be paid a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, November 9th. Organon & Co.’s payout ratio is presently 10.53%.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Allied Private Wealth LLC purchased a new position in shares of Organon & Co. in the 2nd quarter worth about $33,000. Nykredit A S purchased a new stake in shares of Organon & Co. during the 2nd quarter worth about $76,000. GAMMA Investing LLC increased its position in Organon & Co. by 69.8% during the 2nd quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after purchasing an additional 2,376 shares in the last quarter. Wedmont Private Capital acquired a new stake in Organon & Co. during the 2nd quarter worth approximately $136,000. Finally, Ethic Inc. acquired a new stake in Organon & Co. during the 3rd quarter worth approximately $141,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.